Pharmafile Logo

Webcast: How to improve the patient journey through an effective engagement and activation strategy

Watch part two in a series, Evolving Patient Journeys, in which experts from across Inizio explore why, despite best intentions, patient engagement solutions can fall short of expectations.

The global pandemic has caused the health and life science industry to change more in the last three years than it has in the last three decades. The accelerated adoption of digital in all areas of the healthcare landscape has dramatically altered the patient journey.  Now more than ever, healthcare stakeholders need support from pharma to help deliver optimal care to patients.  But are current engagement strategies working as well as they could be?

Watch part two in a series, Evolving Patient Journeys, in which experts from across Inizio explore why, despite best intentions, patient engagement solutions can fall short of expectations.

Using a typical product profile scenario in an area of high unmet need, they will demonstrate how pharmaceutical manufacturers can improve the patient journey through a combination of insight generation, engagement strategy and activation.

Research Partnership Director, Liza Pliss was joined by Nareda Mills, Global President, Patient Solutions at Ashfield Engage and Edward Gajewski, Principal at Nuvera Life Science Consulting.

They will share best-practice and practical insight on how to develop suitable research programs, strategies and initiatives that successfully support stakeholders throughout the journey, improve brand engagement and ultimately improve patient outcomes.

What you will learn:

  • How to gather the right insights for early commercialization and to guide the design of clinical trials
  • How to gain a foundational patient understanding in a new disease area or for a new asset in an area of unmet need
  • How to get a deeper understanding of the changing emotional needs of patients and their new digital behaviours in areas of chronic illness
  • How to deploy engagement tactics throughout the journey and product lifecycle

Watch here

This content was provided by Research Partnership

Company Details

 Latest Content from  Research Partnership 

Free Thinking: Behavioural economics

Our Free Thinking white paper asks, does behavioural economic theory have a role to play in pharmaceutical market research?

Article: The Colombia Conundrum

Published in eye for pharma 30 January by Marc Yates

Ageing in China: The Implications for Healthcare

Published in eye for pharma 12 December by Marc Yates

Exploring MINT: Part 4 – Turkey

In the fourth and final of a series of posts focusing on each of the ‘MINT’ markets, I take an in-depth look at the opportunities and challenges for pharma in...

Getting to grips with Russia’s healthcare market

As a non-Russian, trying to understand the complexities of the multiple overlapping levels of Russia’s healthcare system can be baffling at times. Information is often inaccessible or data simply doesn't...

Exploring MINT: Part 3 – Nigeria

In the third of a series of posts focusing on each of the ‘MINT’ markets, I take an in-depth look at the opportunities and challenges for pharma in Nigeria.

Exploring MINT: Part 2 – Indonesia

In the second of a series of posts focusing on each of the ‘MINT’ markets, I take an in-depth look at the opportunities and challenges for pharma in Indonesia, with...

Free Thinking: Leveraging the ASEAN Market

If you can only research one ASEAN market, which one do you choose?Our Free Thinking paper investigates the opportunities for pharma in ASEAN and outlines the factors you need to...

Free Thinking: Biosimilars: Friend or foe to healthcare?

Our Free Thinking white paper looks at the opportunities for biosimilars and the threats to innovator biologics.